Table 4.
Effect of IPTsc on clinical malaria during the intervention period
| Study site | Drug regime | No of children | Incidence rate per 1000 PYAR | PE (95 % CI) | |
|---|---|---|---|---|---|
| Dicko [23] | Kambila | SP (bimonthly) | … | 2.7a | 40.1 (17.9–56.4) |
| Control | … | 4.5a | – | ||
| Barger Barger [25] | Kollé | SP + AS | 91 | 488 | 67 (42–98) |
| AQ + AS | 97 | 782 | 47 (32–67) | ||
| Placebo | 96 | 1463 | – | ||
| Nankabirwa [27] | Tororo | DP (monthly) | 236 | 0.01 | 97 (87–98) |
| DP (three and five monthly) | 234 | 0.34 | 0.00 | ||
| Placebo | 243 | 0.34 | – |
PE protective effect, No number, SP sulfadoxine-pyrimethamine, SP + AQ sulfadoxine-pyrimethamine plus amodiaquine, SP + AS sulfadoxine-pyrimethamine plus artesunate, DP dihydroartemisinin-piperaquine, … data not available, PYAR person-year at risk
a5–10 years sub-group